A Systemic Closed Loop Electronic Medication Management Approach

Marcus Bowles¹, Jianjun Lu²

Australian Maritime College, University of Tasmania, Launceston 7250, Australia¹
College of Economics and Management, China Agricultural University, Beijing 100083, China²

ABSTRACT: The value of Closed Loop Medication Management (CLMM) systems resides in their ability to help healthcare providers prevent medication errors (ME) and adverse drug events (ADEs) that may occur during the process of delivering prescription medicines [1-5]. This paper argues that the concept of ‘closed loop’ is being incorrectly conceptualised in a linear sense process from the pharmacist to the patient. As a result not only is the process (loop) not being ‘closed’, such thinking is preventing traditional CLMM systems being designed to provide the user functionality required to reduce waste and costs, improve performance, and thence improve patient outcomes through reduction of ME and ADEs. A case will be built for how a ‘closed loop’ medication management process should be conceptualised and results from a Kano Model Analysis presented to isolate the functions and attributes that raise performance and excite users managing medications within a closed loop process. This qualitative study will occur against the backdrop of an ongoing quantitative research based on a study of the innovative Closed Loop Electronic Medication Management (CLEMM) system being trialed in test sites located in Australia and Hong Kong. This will permit current practice and future best practice to be contrasted and the initial impact on improved patient outcomes to be advanced. Through soft systems analysis and user satisfaction studies initial evidence will confirm significant benefit can accrue in aged care or for community pharmacists when managing patient risk, process control, and overall medications systems throughout the loop from the point of supply and packaging through to ensuring that the right patient receives the right dose of the right drug at the right time, and then, beyond to post-delivery reporting and monitoring.

KEYWORDS: Closed Loop Electronic Medication Management System, Medication Errors, Adverse Drug Events, Medication Management System, e-Health

I. INTRODUCTION

The magnitude of medication errors (ME) and resulting adverse drug events (ADEs) has become increasingly apparent over the years since studies began in earnest in the 1990s [6-12]. Research has demonstrated the magnitude and cost of medication-induced breaches in quality care and organisational performance [13-16]. Adverse drug events (ADEs) encompass the concept of harm resulting from the use of a drug. Such events can be non-preventable or preventable (pADE). The concept of pADE is essentially that potential harm can be prevented (e.g. human error), whereas ‘non-preventable’ suggests harm was not considered preventable (e.g. unknown drug-on-drug interaction) [17].

Medication mishaps can occur anywhere in the medication management process. As currently conceptualised the core stages in the process include prescribing, repackaging, dispensing, administering and monitoring. The aim in the management of the medication management process (MMP) (alternatively titled medication management workflow or medication management cycle) is to remove or manage risks associated with potential causes of harm to a patient. Such actions need to occur not just at each point in the process but across all points in the process’s lifecycle [18-20]. If the lifecycle is incorrectly defined, then addressing impediments to patient outcomes through technology enabled medical management interventions will be inherently flawed from the outset.

Medication management systems (MMS) combine in-formation and communication technologies (ICTs) with applications designed to optimise the medication manage-ment process to ensure that the ‘right patient receives the
right drug at the right time’, and that the correct dosage is prescribed [21]. Improved management of medications can promote a patient-centric approach to improving access, governance and overall cost reduction in the total supply chain. This includes such benefits as medication management for remote patients, especially in developing economies.

MMS therefore can potentially go well beyond managing medications from pharmacy to patient at a single site. An MMS solution could span the complete supply chain, any-where in the world, in developed or developing countries. This conceptual reconsideration has profound implications for the management and shipping of drugs. Moreover, the perspective argues improvement to medication management has to expand beyond the current focus on the clinical ‘middle’ part of the medication process. This is because quality can only be guaranteed when problems are also managed in the medication supply chain from the original point of manufacture and after delivery to a patient through to the prescription renewal and the follow-up monitoring. In this sense MMS technologies need to evolve rapidly to promote a truly ‘closed loop’ approach to medication management.

The ‘closed loop’ approach derives its significance from quality hospitals, clinics and nursing homes seeking to integrate ICT in order to control and continuously improve all stages in the MMP. The focus has been on achieving connectivity and reporting even up to the bedside where the nurse issues medicines [22]. In the healthcare setting the closed loop therefore concentrates on deploying technologies that can enable integrated and timely information provision for a patient across all points in the clinical provision of medications, from the doctor to the patient. The aim is to improve quality significantly and prevent errors.

Current efforts to close the loop in medication management also have a single, pervasive flaw: the loop does not encompass the lifecycle of the medication management requirement or provide a systems-level view of each medication management episode of care. As a result most existing closed loop medication management (CLMM) technologies fail to provide fully integrated capability to manage pre-pharmacy packaging or supply from the manufacturer, as well as follow-up and prescription renewal stages after delivery of the medication to the patient. It will be argued these omissions respectively limit the ability to reduce errors and costs introduced into the clinical loop through fraud (counterfeiting, diversion and substitution) or waste.

All parts of the process must be addressed and variations removed before a single component of the MMP can be optimally improved. For complete closure of the loop the complete medication lifecycle (loop) has to be under control. This requires a fundamental extension of current technologies and the current paradigm associated with the medication management process to encompass the supply chain management conceptualisation of the closed loop. This concept assumes it is equally important to manage the problems introduced into the process prior to or even after the clinical ‘loop’ that has traditionally covered the journey between prescription and patients’ receipt of medications.

In this paper, we investigate a new CLMM system, the Closed Loop Electronic Medication Management (CLEMM). It describes the advanced features required to close the loop of an MMP fully, confirms user satisfaction with the solution and confirms the potential of the new systems ahead of traditional medicine management solutions.

II. KEY DIMENSIONS TO THE STUDY

The following section confirms some of the main contextual issues in order to refine our appreciation for the role and function of a closed loop approach to medication management.

Medication Errors and Adverse Drug Events: A medication error is any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the healthcare professional, patient, or consumer. Such events may be related to professional practice, healthcare products, procedures, and systems, including: prescribing; order communication; product labelling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use [7].
Adverse drug events (ADEs) are injuries resulting from the use of a drug. Such events can be non-preventable or preventable (pADE). The concept of pADE is that potential harm can be prevented (e.g. human error), whereas ‘non-preventable’ suggests harm was not considered pre-ventable (e.g. unknown drug-on-drug interaction) [17].

Whereas research in the last decade of the twentieth century quantified the breadth and depth of the problem, re-search in this century has focused on the exact nature of the problem. The conclusion from global research is that medi-cation errors (ME) and adverse drug events (ADEs) result in problems that are a substantial, pervasive and very signifi-cant—if not major—cause of events that lead to disability and death. Research estimates that ME in the United States (USA) for the year 2005 caused 218,000 deaths, cost up to $130 billion [23], resulted in 400,000 preventable ADEs and harmed at least 1.5 million patients [24]. In the United Kingdom (UK), as in the USA, 1 to 2 per cent of patients in hospitals are thought to be harmed by ME arising within the medication management process [25]. In Australia, albeit 1 per cent of patients admitted to hospitals may experience ADEs [26], studies indicate 2 to 3 per cent of hospital ad-missions are medication-related, which alone translated into a cost of AUD$660 million per annum in 2008 [27].

Global studies mirror the results from the USA, the UK and Australia. Studies in multiple countries suggest some 5 to 8 per cent of all hospital admissions [27] result from ME and 6.5 patients in every 100 admitted to a hospital will experience ADEs that can lead to death or disability [28]. In at least comparative terms, the numbers of reported ME and ADEs are growing everywhere, regardless of the healthcare system, institutional setting (hospital, nursing or aged care homes, or community health) [20, 23, 29], or professional (e.g. doctor, clinician, pharmacist, nurse, administrator) studied in the medicine management process [30].

The occurrences of ME and ADEs have a close relation-ship with stages in the medication management process. As also evidenced by data from elsewhere the National Patient Safety Agency (NPSA), which collected data on ME and ADE in the National Health Service of UK, confirmed the most error-prone stage to be administration/supply, rather than the latter phases of the medication management process. Three incident types – unclear/wrong dose or frequency, wrong medicine and omitted/delayed medicines – accounted for 71 per cent of fatal and serious harm from medication incidents [31].

Work since the early 1990s on the use of computerised equipment to prevent ADEs in hospital patients [32] and extensive research since has generated strong evidence for the efficacy of deploying technology to reduce ME and ADE in the medication management process. Interventions in-clude use of ICTs to address classified causes of ME. Although countries have pursued national approaches and investment in e-prescriptions, administration of medicines [33, 34] or national personally controlled electronic health records (PcEHR) [35], research has continued to confirm that using computerised physician order entry systems (CPOES), clinical information systems associated with electronic medication management and barcode medication tracking systems can provide enormous cost savings by preventing ME and ADE [24, 36-38].

Yet the adoption and use of ICT in medication manage-ment has generated its own problems. AbhaAgrawal draws attention to three of the most significant [24]:

- Scepticism about the evidence and claims made regarding the impact and cost savings of such sys-tems on clinical outcomes.
- The evidence of potential negative consequences of IT systems on patient safety and the generation of new opportunities for ADEs arising from systems that require clinical care and existing workflows to change to suit the technology.
- That prevention is not just about focusing on the IT system itself, but also on how and who has to im-plement the technology.

**Medication Management Systems:**

MMS combine information and communication technologies (ICTs) with applications designed to optimise the MMP to ensure that the ‘right patient receives the right drug at the right time’, and at the correct dosage [21]. The use of ICT to enable medication management has been promoted by extensive research and national studies on ME and ADEs which have found the following:
Medication administered to a patient has to be managed from the point of prescription through every stage and human intervention in the medication use process;

• A medication order should contain all necessary items in such a way that it is managed once and administered in a single, transparent document (single copy);

• The patient should be identifiable in a unique manner;

• The consequences and costs of preventing ADEs are appreciable when it is recognised they are the most common cause of harm to hospitalised patients and can be significantly mitigated or avoided by means of electronic reporting and MMS;

• Every MMS needs to be implemented across disciplines and even locations;

• Ongoing drug innovations and approvals necessitate an up-to-date drug database directly accessible to each practitioner in the medication supply chain; and

• All medication administration should be able to document and register all activities by uniquely linking a patient to identified medication orders.

Medication management is a fast-growing niche within the e-Health or health IT segment. Efforts are advancing in the USA, Europe and select Asian countries, and increasingly in Australasia, to implement systems that provide much-needed clinical decision support, electronic prescription and other related features.

Electronic MMS in this context refers to use of Internet-connected devices to regulate, manage and improve the MMP, each and every time a patient enters the cycle to access prescription medications for prevention and treatment purposes. This is done through a central, common view that spans different care providers associated with delivery of prescribed medications to a single patient. Electronic MMS may therefore find application beyond a single site such as a hospital, clinic or nursing home. Medication management and, in particular, closed loop approaches must ensure that each episode of care (every cycle) in the MMP for a patient is not only managed but linked to the patient’s electronic medical records. The low level of successful implementation of these systems in hospitals, nursing homes and clinics is of concern, however, given the increasing need for an effective solution.

MMS therefore can potentially go well beyond managing medications from clinician prescription to a specific patient at a single site. An MMS solution could span the complete supply chain, anywhere in the world, in developed or developing countries. If the perspective is expanded beyond the clinician to patient linear process to a system of medication management, quality can only be guaranteed where problems are managed in the medication supply chain from the original point of manufacture and after delivery to a patient right through to the prescription renewal and the follow-up monitoring. In this sense MMS technologies need to evolve rapidly to promote a truly closed loop approach across the entire chain that constitutes medication management.

Closed Loop Medicine Management (CLMM):
Closed loop has focused on using technology to achieve connectivity and reporting from the point when the clinician writes the prescription up to the bedside where the nurse or carer issues medicines [22]. In the healthcare setting closed loop therefore concentrates on deploying technologies that can enable an integrated, timely information provision for a patient across all points in the clinical medication management process, from the doctor to the patient. The aim is significantly to improve quality and prevent errors.

Closimg the loop in the medicine management process essentially means using different technologies for the following purposes:

• Prescription and Order Writing
  - E-Prescribing
  - Computerised physician order entry (CPOE) systems
  - Clinical data repository (CDR)
  - Drug information systems/databases
  - E-Pharmacy and pharmacy ordering and information systems
• Automating Drug Dispensing and Administration
  - Barcode technologies
  - Nanotechnologies
  - Radio-frequency identification (RFID)
Addressing Medication Errors in Various Areas of Care Delivery

- Automating emergency department care processes
- Automating bedside care processes
- Automating perioperative care processes
- Preventing medication errors at patient discharge

Electronic medication reporting and medication reconciliation span all stages including confirming that medications are supplied at each and every stage in the process and over different cycles (episodes of medication care provision) to the agreed specifications. Closure of the loop cannot therefore focus solely on a single episode of care. Even with the multiple solutions and their often extensive features, the focus still tends to be on the clinical aspects of the medication management loop. These aspects do not necessarily support the non-clinical, supply chain management view of the medication management value chain.

The clinical concept of a closed loop system is quite unlike that used in supply chain management. In this setting, the term goes even further to encompass a value chain that:

- Considers the full lifecycle of a product, including its expected use after fulfillment and waste management [39];
- Ensures that value chain design has a forward and a reverse logistics element associated with the recovery of unused products, confirmation of actual usage patterns, and disposal of used products or waste associated with the supply of a product (e.g. packaging) [40];
- Ensures that replenishment and new orders are continuously linked with the product end-of-life as supplied (e.g. use-by date) [41] or reverse cycle in the closed loop;
- Offers direct reuse or replacement and quality review of product or services during the ‘return loop’ in a closed loop supply chain [42].

This extended focus is essential in assessment of the potential of any closed loop medication management solution. It ensures that the loop (process) is not closed in the linear sense from the pharmacist to the patient. This is of critical importance to pharmacists that may be working to serve community and aged care or nursing homes [20, 21, 43]. The process has to be considered as a cycle encompassing all points involved in delivering medications to the patient. This extends traditional CLMMS beyond controlling single points to close the information loop that informs those paying for medications (government benefits schemes, insurers, etc.), pharmaceutical manufacturers and non-clinical supply chain partners.

The extended view of the closed loop above (Figure 1) illustrates how CLMMS can be used to encompass the non-clinical aspects of supply and the subsequent use/non-use of the medication. It encourages the improved systems-level flow of information that can drive an increase in quality of care, removal of waste and cost savings. This loop covers a patient over the life of the medications prescribed, across each medication episode of care provided over time, and beyond any single point in a cycle.

Literature and case review on user satisfaction with CLMMS systems confirms an ongoing emphasis on the following deployment functions and features.
### Table 1: Existing CLMM systems user desired attributes

| Supply & Packaging | Easy and simple operation  
|                   | Accurate labelling and packaging of packages/prescribed items  
|                   | Ability to quickly prepare drug packs  
|                   | Support for barcodes to ensure accurate drug and patient identification  
|                   | Support for staff interruptions that are known to increase risk of error  
|                   | Facilitate pharmacist review and support to packers  
|                   | Guidance for methodical checking  
|                   | Support low skilled staff to perform reliably and efficiently  
| Prescription to Patient receipt | Eliminate transcription and illegibility errors  
|                               | Reduce errors of omission (administration)  
|                               | Facilitate pharmacist review and support to prescriber  
|                               | Streamline drug administration without adding to workload or time required to complete drug round  
|                               | Support for staff interruptions that are known to increase risk of error  
|                               | Support low skilled staff to perform reliably and efficiently  
| Monitoring/Reporting | Enhance pharmacist reporting on prevention of ADEs through incompatible drugs being prescribed to the same patient  
|                      | Information on packing and administration tasks to reveal variances, inconsistencies for process improvement and monitoring  
|                      | Evidence of quality control and monitoring for accreditation and clinical governance requirements  
|                      | Precise information about stock utilisation for stock and cost control  
| Overall | Ease of use for medication management tasks and reporting requirements  
|           | Security of data and interoperability of system with existing health information systems  
|           | Ubiquitous access to data and patient records by authorized personnel  
|           | Suitability for low skilled workforce supported by smaller professional team  
|           | Non-disruptive to existing workflows and practices  
|           | Process standardisation for medication packing, administration and overall management  

### III. CLOSED LOOP ELECTRONIC MEDICATION MANAGEMENT SYSTEM (CLEMM)

**System (CLEMM) Description:**
A breakthrough clinical solution called the Closed Loop Medication Management system (CLEMM) offers insights into the features of a more effective approach to CLMM. CLEMM is an integrated solution that resides in the clinical information systems component of the e-Health or health IT market segment of the healthcare industry. CLEMM can satisfy existing and expanding demand in the two largest parts of the e-Health vertical segment within healthcare: clinical information systems and secondary specialised usage non-clinical systems. CLEMM is distinct from traditional closed loop medicine management (CLMM) technologies for the following reasons:

- it assists clinicians or pharmacists with patient risk and process control;
- it manages medications to remove ADE from the point of packaging through to ensuring the right patient receives the right dose of the right drug at the right time;
- it offers end-to-end coverage across all aspects of the medication management process;
- it offers a single, integrated system that includes all the hardware and software required to achieve a more robust, value-adding closed loop approach than is currently available in the market.
Medication management, including medication packaging and administration, accounts for a large amount of the resources spent on health (Expenditure in the medicine-related pharmaceutical segment of global packaging is forecast to grow by 20 percent from 2014 to reach US$25b in 2019[52]. CLEMM uniquely addresses the need for medication management in poorly resourced and high-volume environments. In under-resourced, high-volume or regionally dispersed healthcare systems, the challenge is greatest. Until now, no solution was sufficiently scalable, flexible or affordable to address user needs. Conventional e-Health solutions are capital-intensive, enterprise-style systems suited to a top-down approach. In contrast, the CLEMM system uses existing infrastructure and is a highly adaptable managed service.

CLEMM is an MMS that provides point-to-point risk and process control, especially from pharmacist-to-patient, to ensure that the right drug reaches the right patient at the right time. The beauty of CLEMM is that it empowers medical and healthcare staff to work together across points in the medication management process to improve medication safety in areas such as packing, review, management and administration. This ability completely closes the medication management loop.

CLEMM is fully integrated from drug packaging through to administration, and provides a full audit trail for process control and accountability. Designed to enable the full utilisation of pharmacy services, CLEMM offers clinicians, pharmacists and care providers a convenient way to provide remote support and expert advice. Delivered as a managed service, the system is non-capital-intensive, uses existing infrastructure, is easy to deploy and is designed specifically for healthcare environments where staff and resources are limited.

Table 2: CLEMM system

<table>
<thead>
<tr>
<th>Medication management</th>
<th>Medication list, Dose admin plan, Patients, Prescribers, orders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consumer applications</td>
<td>Health roaming, Dosing reminder, Packing</td>
</tr>
<tr>
<td>Blister pack preparation</td>
<td>Prepare layout, Preview, Print, Unit dose, Multi dose, PRN, Batch scheduling</td>
</tr>
<tr>
<td>Light-speed packing</td>
<td>Filling, Checking, Assembly, Delivery, Returns</td>
</tr>
<tr>
<td>Remote requests</td>
<td>New drug, Changes</td>
</tr>
<tr>
<td>Prescriber alerts</td>
<td>Approve new drug, Approve changes, New indication</td>
</tr>
<tr>
<td>Pharmacist alerts</td>
<td>Changes, Missed doses, New drug</td>
</tr>
<tr>
<td>Dose administration</td>
<td>Regular medications, PRN medications, Imprest medications, Drug request</td>
</tr>
<tr>
<td>System management</td>
<td>Configure batches, Users, Institutions, Drug list, Registration, Utilities</td>
</tr>
<tr>
<td>Billing system</td>
<td>Transaction log</td>
</tr>
</tbody>
</table>

IV. THE FEATURES OF CLEMM

CLEMM Closes the Loop:
Simply concentrating on an institution’s internal clinical MMP will not reduce errors and waste introduced in previous cycles. Systems-level improvement requires closing the loop in all parts of the medications supply chain, delivery and subsequent use by a patient.

As depicted below the CLEMM software supports the administration, reconciliation and reporting required to close the complete loop across all points in the medication management process.
Figure 2: CLEMM spans all points in the full lifecycle of a closed loop medication management process
In the context of a more sophisticated and accurate understanding of the loop that constitutes the medication management process and each subsequent cycle of care a patient may enter, the CLEMM solution delivers a strong value proposition:

- The CLEMM solution is easy to use because it uses existing infrastructure and widely deployed mobile devices.
- CLEMM can be implemented quickly without significant skill requirements.
- As it is a managed service customers pay per use and have no capital costs or operational overheads sunk into technology or infrastructure.
- CLEMM ensures closed loop accountability seamlessly spans clinical, regulator and supply chain aspects.
- CLEMM supports a high-quality care continuum that is patient-centric.
- CLEMM reinforces existing, effective workflows and practices.
- CLEMM gives ubiquitous access, anytime, through multiple devices.

CLEMM is a Single System
CLEMM no longer requires multiple applications, technologies or systems. It is a single system with integrated features and benefits (tables 2, 3 and 4).

<table>
<thead>
<tr>
<th>Features</th>
<th>Benefits</th>
</tr>
</thead>
</table>
| Pharmacist definition of patient medication packing template | • Removes guesswork for low-skilled staff  
• Can be performed remotely for efficiency and convenience  
• Enables full utilisation of pharmacy services |
| Barcode scan of medications being packed      | • Ensures that correct medication is selected and correctly packed  |
| Integrated within CLEMM dose administration system | • Provides full medication audit trail for accountability and automated record keeping  |
| Medication changes                            | • Facilitates and manages medication changes and schedules the change for packing  |
| Colour-coded backlit display                  | • Makes packing – an error-prone task – easy to perform                   |
Table 3: Drug Packaging

<table>
<thead>
<tr>
<th>Features</th>
<th>Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrated Light-Speed Drug Packaging</td>
<td>Full audit trail from packaging through to administration – closed loop medication management</td>
</tr>
<tr>
<td>Barcode-confirmed dose administration</td>
<td>Confirms correct patient, medication and time and records administration to close the loop</td>
</tr>
<tr>
<td>View of patient allergies</td>
<td>Increases patient safety</td>
</tr>
<tr>
<td>New medication request</td>
<td>Sent by administering nurse to doctor’s smartphone for review and approval or rejection</td>
</tr>
<tr>
<td>Medication requests and approvals</td>
<td>Enables medical professionals to review and approve medication requests remotely</td>
</tr>
<tr>
<td>Smartphone alert</td>
<td>Enables low-skilled staff administering medications conveniently to contact medical professionals for guidance Alert details are sent to professional for review</td>
</tr>
</tbody>
</table>

Table 4: Dose Administration System

<table>
<thead>
<tr>
<th>Features</th>
<th>Benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smartphone-accessed medication list summary</td>
<td>Enables patient conveniently to access personal medication list wherever and whenever they need to</td>
</tr>
<tr>
<td>Dose reminders for in-community medication administration</td>
<td>Enables governments to fully monitor the use of medication, even in the community</td>
</tr>
<tr>
<td>Medication diary for review with doctor</td>
<td>Summarises medication consumption and includes opportunity for patient to respond to questions about symptom resolution</td>
</tr>
</tbody>
</table>

Table 5: Health Roaming

**Clinicians not Technology Drive Workflows:**
CLEMM is seemingly designed to complement existing workflows. Neither clinical practice nor existing work practices have to be amended to adopt and implement the technology.

Figure 3: Workflows of New Drug Request
CLEMM Features:

Ubiquity: CLEMM can be accessed anytime, on any Inter-net-connected mobile device, anywhere—whether in urban or rural settings, or in developed or developing countries. The model has a practical impact on improving the delivery of healthcare in rural areas that suffer from isolation, small size, scattered populations and a limited resource base. Implementing CLEMM can therefore ensure the democratisation of access, especially in developing countries.

CLEMM is device-agnostic. It can be accessed via multi-ple technologies and networks. Its primary model is Inter-net-connected mobile devices using 3G cellular or wireless broadband networks. Given the global penetration and familiarity of mobile phones this approach ensures a very low threshold to competent use by medical professionals, ancillary service providers and patients.

Closed Loop Deployment: CLEMM delivers on the mantra that the right patient receives the right drug at the right dose and at the right time. Moreover CLEMM removes variations during the supply and after the delivery of prescribed medications to the patient to include subsequent episodes of care. Thus CLEMM closes the loop before and after a single medication management process.

CLEMM is designed on the fundamental premise that medication management needs a patient-centric view that slices across the horizontal to encompass all those involved in the process of care. This is distinct from outmoded approaches that try to impose linear control between points of care that are discrete parts of the overall medication management process.

CLEMM empowers healthcare providers by providing a central repository for electronic patient medical records such as history, medication and problem notes, and allergies. Because the information is digital it can easily integrate with existing electronic health record systems and platforms. The system also allows multiple people or disciplines involved in a patient’s healthcare to share information, thereby reducing potential medical errors, facilitating urgent decisions, and sharing and confirming a diagnosis. All this can occur at anytime and anywhere around the globe.

CLEMM can be deployed rapidly to achieve immediate efficiencies and improve overall management. Early wins guarantee that each step in the medication management process adds value, removing barriers to improving cost efficiency or quality clinical and patient outcomes (e.g. removing errors, delays, waste).

Through the use of a plug-in application CLEMM can access drug information databases or therapeutic information for medicines. This offers the potential to trigger a drug-drug clinical alert when a combination of certain medicines may lead to harmful effects on a patient.

Security:

Another feature of the CLEMM portal alongside interop-eration and integration with existing technologies and communications networks is its ability to securely manage the increased volume of data associated with e-Health reform [37]. The cloud-based Internet portal for CLEMM permits managed access permissions and protection of critical data that is stored on- or off-site. This means a security layer augments user access and administrators control user accounts and what a user has permission to access.

The security layer and authentication enforce protocols and user requirements in terms of prevention of data loss and unauthorised intrusion, promotion of easy access for au-thorised users, control of network access, and management of privacy or other regulatory requirements.

Data standards and integrity reconciliation have also be-come a major issue in global healthcare. Problems include classification and standardisation of medication data across institutions, healthcare providers, medication management supply chain partners, and countries. To overcome such problems CLEMM uses medication reconciliation and standards in relation to classification and listing of drugs.
Medication reconciliation is the standardised process of obtaining a complete and accurate medication history and in the context of the plan for care comparing it with admission, transfer or discharge medication orders [45]. This concept reinforces the broad need to ensure that medications can be reconciled at any point, continuously throughout all stages in the medication management process. To achieve this outcome in any system, and across both supply side and clinical side, management of medication standards is required.

To effectively complete reconciliation all stakeholders involved in reporting require a standardised or, at minimum, a benchmark set of medication definitions against which other definitions can be compared. The CLEMM solution uses the medication list, which is a complete and comprehensive list of medicines with sufficient information for full identification of all products. Key elements include the name(s), strength, and dose form and directions for use [18]. In addition CLEMM has a plug-in that permits the use of standardised terminology. CLEMM is compliant with Australian medicine terminology. This ensures standardised use of medication terminology across all partners in the medication management process, whether supply chain (non-clinical) or clinical people, enterprises and systems. This optimises the integrity of the data and reporting systems. CLEMM also has a plug-in that permits users to access multiple drug databases.

**Ease of Use:**
CLEMM does not require a long learning curve. Users of mobile devices can intuitively use the application. Merging communications technology and networks optimises usability. CLEMM fits with the existing workflow so no change is required by clinicians in terms of their existing practices when they adopt the technology.

**Speed of Implementation:**
CLEMM is a ‘turn-key’ solution. This means it is ready to go to suit the user’s needs. It can be adopted at a micro level and scale up to meet any level of demand. CLEMM leverages what exists: technology, networks, skills and workflows. In addition no protracted procurement processes are required to buy expensive technologies or enhance communications infrastructure. CLEMM harnesses existing or low-cost mobile handsets or devices that connect by using existing cellular or wireless network infrastructure.

**V. TRIALS OF CLEMM**

**Methodology:**
Prior to field trials it was considered critical that the user requirements and the functions or features of existing CLMM systems be confirmed and user satisfaction determined. Consistent with studying innovation in information and communication technology within health settings the Kano Model Analysis was used to identify not only user requirements for improved CLMM systems [46], but also isolate the technical features or feature that would have the most impact on improved deployment [47]. Kano attributes span three levels:

- **Threshold** - "Must Have", cannot sell it without it, but low op-portunity for product differentiation.
- **Performance** - "More Please", the more the merrier, if they are weak in the product they will reduce satisfaction but they do offer an opportunity to be strong and grow satisfaction and product differentiation.
- **Excitement** - "WOW", unknown but highly desired, these provide unique satisfiers and a great opportunity for providing product differentiation [48].

Using the rating scales below initial interviews were conducted with users (e.g. clinicians nurses, pharmacists, dispensary clerks) to rank the importance for any new CLMM system to have certain attributes (as listed previously in Table 1).

A. Satisfied;

B. Neutral (Its normally that way);

C. Dissatisfied;

D. Don’t care.

Expert groups were then convened to confirm these attributes. Kano Model Analysis confirmed had 25 percent of the CLEMM solution consolidated threshold attributes, 44 percent reinforced emerging strengths in performance at-tributes, and nearly a third (31 percent) leveraged functions (packaging, labelling, reporting) were considered by users to be
‘exciting’ new attributes. The table below indicates not only the importance of the attributes but the initial satisfaction of users with the CLEMM solution after the first round of implementation in the trials.

<table>
<thead>
<tr>
<th>User Satisfaction Attributes</th>
<th>Kano Criteria</th>
<th>Product Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ability to learn to pack patient medications</td>
<td>Threshold</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to learn to administer medications</td>
<td>Threshold</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to learn and confirm correct drug packing instructions</td>
<td>Threshold</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to learn how to report on drug packing and administration activities</td>
<td>Excitement</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to rapidly administer medications</td>
<td>Performance</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to accurately administer medications</td>
<td>Threshold</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to rapidly pack medications</td>
<td>Performance</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to accurately pack medications</td>
<td>Threshold</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to identify and correct packing errors before drug administration</td>
<td>Threshold</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to avoid adverse drug events (reporting and data integration)</td>
<td>Excitement</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to seek assistance during drug rounds or packing</td>
<td>Excitement</td>
<td>N</td>
</tr>
<tr>
<td>Ability to report on drug packing and administration activity to identify delays and omissions</td>
<td>Excitement</td>
<td>P</td>
</tr>
<tr>
<td>Ability to standardise processes for packing and administration staff</td>
<td>Performance</td>
<td>P</td>
</tr>
<tr>
<td>Ability to introduce system with minimal training</td>
<td>Performance</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to introduce system with minimal staff resistance</td>
<td>Performance</td>
<td>Y</td>
</tr>
<tr>
<td>Ability to introduce system with minimal technical issues</td>
<td>Performance</td>
<td>Y</td>
</tr>
</tbody>
</table>

Table 6: Kano ranking of attributes and priority drivers for user satisfaction with CLEMM System

Product fit ranking related to whether the overall user feedback confirmed if CLEMM system being reviewed had the attribute: Y – Yes, N – No, P – Partial, RM - On Roadmap (being developed before full deployment).

While this research will continue with users it must be acknowledged research is ongoing. In particular the quantitative analysis of the impact on such factors as patient care and process efficiency will be covered in later publications. This includes research surrounding CLEMM trials where its usability, ease of deployment, information and decision requirements performance were tested. Two pilot projects were conducted: (1) a Hong Kong nursing home, for four months; (2) an Australian-based nursing homes trial as part of the Personalised Electronic Health Records e-Health Trial to be completed in early 2016.

There are three broad methodologies that are relevant to conducting research and testing in relation to these longer term, quantitative pilots. Quantitative assessments involve capturing numerical data on activities of interest, for example the cost, time, volume or frequency of particular events. This type of data is likely to be of particular interest to groups evaluating the overall benefits of CLEMM; for example, in understanding cost and time savings within the medication-related activities, medication-related cost savings, and impact on reducing adverse drug events. It is likely that quantitative information
will play a primary role in the initial marketing of CLEMM, and also be useful for groups that are not directly involved in hands-on medication-related activities themselves (e.g. healthcare funders and healthcare services organisations).

Qualitative assessments involve capturing general observations or people’s experiences, as a means to develop broad understanding or model a situation. In terms of CLEMM trials, this information is likely to centre on structured interviews or casual discussions with people using CLEMM. It may assist with user statements on areas of benefit or areas for possible improvement, tips on services or assistance that can be provided in the adoption process, and gathering stories on improved patient outcomes or CLEMM-enabled ‘wins’.

Grounded theory involves developing an overall theory or model of a situation based primarily on qualitative observations [49]. It is achieved through careful review and categorisation of qualitative evidence, as a means to identify an explanatory model or theory that emerges from the research data. Although this approach is usually conducted by a researcher first-hand to gather a diverse and rich array of research data, it is likely to be useful in research associated with medication management to identify phenomena and behaviours that form an improved basis for formulating a structured explanation of current practices and a set of propositions that can underpin a more robust understanding of the closed loop theoretical model. Grounded theory is well positioned to complement action research approaches and may be modified to review and integrate observations across all trials in a summative manner.

VI. IMPLICATIONS OF THE RESEARCH

While this study raises the need to change our perspective on ‘closed loop’ and capability of emerging systems such as the CLEMM system, it remains early days in terms of the impact this changed perspective on the process of medication management and resulting innovation to improve the functional design and attributes associated with existing CLMM systems. Evidence supports persisting with this approach as the removal of restrictions associated with traditional concepts of closed loop and MMS is tightly tied to and user satisfaction with the CLEMM system being trialled. In particular the user excitement over functions and attributes that improve speed, accuracy and integration of sup-ply-side packaging and labelling with correct administration of medications and the subsequent re-ordering and monitoring activities that can occur through electronic reporting. While substantially qualitative in nature the initial research provides significant, positive evidence to suggest the longitudinal studies on the quantitative impact on patient outcomes will be equally positive.

While Australian trials are ongoing in terms of reporting quantifiable patient outcomes and process improvement, initial post-trial structured user satisfaction interviews in nursing home and pharmacy users indicate significant gains:

- The system processes are capturing 100% of packing errors when reconciled to order
- Online access to incompatible drug checking is highly valued by pharmacists and clinicians
- Spell check and accuracy of labels and transcribed scripts
- Zero errors were introduced in the transition of the dosing system, how many were not caught by the system
- Positive user feedback on the system regarding improved the efficiency of their work
- Positive user feedback that the system has improved the safety of their processes and procedures
- Positive user feedback that the system has improved their confidence in the accuracy of their work, or reduced their stress

In terms of packaging and performance:

- More packs are being packed
- Average packs per week total have attained a 20% improvement
- Average time to package medications has reduced by 215 to 109 seconds
- Packaging labels and barcodes have attained zero errors
- Dose administration confirms
- Key staff using packaging and reporting technologies

Implementing new ICT in healthcare is often a delicate balancing act between the potential of significant quality and efficiency improvements [37, 50, 51] and the difficulties of executing the transformation. The impact of ICT has dramatically changed the landscape of healthcare around the globe. By and large the potential of cost reduction,
improved access and quality of services has been heavily offset by the difficulties associated with technology adoption. These difficulties include financing innovative solutions, integrating different technologies and networks, unwanted changes to accepted work practices, extensive reskilling of users and, ultimately, highly visible examples of the failure to deliver initiatives on budget or on time. All these factors reinforce a dark side to ICT adoption that tends to make all stakeholders in healthcare increasingly cautious.

CLEMM is far ahead of traditional medicine management solutions, which were costly and complex and typically required long lead times to achieve effective deployment. Around the globe healthcare providers face the challenge of providing effective medication management in ever-extending supply chains that span disciplines, service providers, and even geographic locations. This has significantly increased the complexity of service delivery and accounted for accelerated costs. The ability to provide equity of access to medication and quality healthcare services is under threat, especially in regional areas.

CLEMM is a breakthrough in terms of how ICT can improve healthcare delivery associated with medication management. As with many important breakthroughs CLEMM is an elegant solution that draws on existing global practices and employs a compelling business model. Using smart, mobile technology and communication networks CLEMM returns control to those directly responsible for delivering healthcare to the patient. Moreover, it is a ‘turnkey’ solution requiring no upfront capital expenditure or reinvestment in new skills or technology.

In the world of e-Health there is often a significant gap between the imperative of those funding ICT initiatives and medical professionals responsible for implementing the technology. CLEMM was not only developed to meet the closed loop medication management requirements of funding bodies, but was also designed by people who have worked in or been responsible for implementing ICT in medication management processes around the globe. CLEMM is therefore designed to improve access anywhere at any time and to ease adoption without sacrificing the improvements to quality or efficiency which all stakeholders demand.

The healthcare market is extremely fragmented. This often makes it hard to position technology in a market, let alone accurately determine the customer or commercial benefits. CLEMM integrates packaging, supply chain management, clinical information systems, medication management and electronic reporting capabilities that individually and collectively hold significant market attractiveness in the broader healthcare, pharmaceutical, medicine packaging, medicine management, mobile health (m-Health) and e-Health segments. For existing and emerging companies in all these growing market segments CLEMM offers a differentiated business solution that combines both clinical and commercial appeal.

**VII. CONCLUSION**

Around the globe healthcare providers face the challenge of providing effective medication management in ever-extending supply chains that span disciplines, service providers, and even geographic locations. This has significantly increased the complexity of service delivery and accounted for accelerated costs. The ability to provide equity of access to medication and quality healthcare services is under threat, especially in regional areas.

Previous solutions have required a large upfront investment in infrastructure, delivery management, training and improvement for the integration of electronic reporting with the management of medications from point of prescription to the patient.

Current efforts to close the loop in medication management also have a single, pervasive flaw: the loop does not encompass the lifecycle of the medication management requirement or provide a systems-level view for each medication management episode of care. As a result most existing closed loop medication management (CLMM) technologies fail to manage pre-pharmacy packaging and supply by the manufacturer. Equally, the follow-up and prescription renewal stages after delivery of the medication to the patient are omitted. These omissions limit the ability to reduce errors and costs introduced into the clinical loop through fraud (counterfeiting, diversion and substitution) or waste. All parts of the process must be addressed before a single component of the medication management process (MMP) can be fully improved. To fully close the loop the complete medication lifecycle (loop) has to be under control. This
requires a fundamental extension of current technologies and the current paradigm associated with the medication management process to encompass the supply chain management conceptualisation of ‘closed loop’. This concept assumes it is equally important to manage the problems introduced into the process prior to or even after the clinical ‘loop’ that has traditionally spanned the chain from prescription to patient receipt of medications.

As evidence of how revised views on a closed loop can enhance the MMP this paper has studied the Closed Loop Electronic Medication Management system, which inte-grates packaging, supply chain management, clinical information systems, medication management and electronic reporting capabilities. Such capabilities reinforce both the linear clinician-patient process and the secondary systems-level loop that spans the whole of the medication supply chain. The features of CLEMM, that individually and collectively hold significant market attractiveness in the broader healthcare, pharmaceutical, medicines packaging, medicine management, mobile health (m-Health) and e-Health segments. CLEMM is far ahead of early CLMM solutions that have typically been costly, required changes to workflows or added complexity and often required long lead times to achieve effective deployment.

CLEMM is a breakthrough in terms of how ICT can improve healthcare delivery associated with medication management. As with many important breakthroughs CLEMM is an elegant solution that draws on existing global practices and employs a compelling business model. Using smart, mobile technology and communication networks CLEMM returns control to those directly responsible for delivering healthcare to the patient. Moreover, it is a ‘turnkey’ solution requiring no upfront capital expenditure or reinvestment in new skills or technology.

CLEMM was not only developed to solve the closed loop medication management requirements of funding bodies, but was also designed by people who have worked in or been responsible for implementing ICT in medication management processes around the globe. CLEMM is therefore designed to improve access anywhere at any time and to ease adoption without sacrificing improvements to quality or efficiency.

REFERENCES

International Journal of Innovative Research in Science, Engineering and Technology

(An ISO 3297: 2007 Certified Organization)

Vol. 4, Issue 9, September 2015


[33] Canada National System for Incident Reporting (NSIR): External field review (efr) results for the national system for incident reporting. Ottawa, Canadian Institute for Health Information, 2009.


